International immunopharmacology · 2026
Cellular and molecular mechanisms of photobiomodulation: A scoping review on therapeutic potential for multiple sclerosis.
СтатьяScoping ReviewНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Linli, Zhou Shaojiong, Jia Huizhu, Qi Yifan, Zhang Cunjin, Wan Hejia, Jiang Meiling
Аннотация
BACKGROUND: Multiple sclerosis (MS) is an immune-driven inflammatory demyelinating disease of the central nervous system. Photobiomodulation (PBM) has emerged as a promising non-invasive therapeutic strategy for MS; however, the underlying cellular and molecular mechanisms remain incompletely elucidated.
OBJECTIVE: This scoping review aimed to synthesize preclinical and clinical evidence to delineate the mechanistic pathways of photobiomodulation for multiple sclerosis, while defining the boundaries of this research field, mapping the current literature landscape, and identifying critical knowledge gaps and key unresolved issues.
STUDY DESIGN: A scoping review conducted in accordance with the PRISMA 2020 guidelines.
METHODS: Database searches were conducted to identify relevant peer-reviewed preclinical and clinical studies. Evidence on the mechanistic pathways, biological activities, and therapeutic effects of photobiomodulation for multiple sclerosis was synthesized and coordinated across in animal and human clinical models.
RESULTS: Photobiomodulation markedly enhances mitochondrial bioenergetics, exerts potent antioxidative stress and anti-inflammatory effects, modulates neuroimmune-glial crosstalk, and strengthens cellular neuroprotective plasticity.
CONCLUSION: The synthesized evidence confirms the remarkable therapeutic potential of PBM in multiple sclerosis. The mechanistic insights derived from this review provide a rational basis for optimizing PBM therapeutic regimens and accelerating its clinical translation for the management of MS.
OBJECTIVE: This scoping review aimed to synthesize preclinical and clinical evidence to delineate the mechanistic pathways of photobiomodulation for multiple sclerosis, while defining the boundaries of this research field, mapping the current literature landscape, and identifying critical knowledge gaps and key unresolved issues.
STUDY DESIGN: A scoping review conducted in accordance with the PRISMA 2020 guidelines.
METHODS: Database searches were conducted to identify relevant peer-reviewed preclinical and clinical studies. Evidence on the mechanistic pathways, biological activities, and therapeutic effects of photobiomodulation for multiple sclerosis was synthesized and coordinated across in animal and human clinical models.
RESULTS: Photobiomodulation markedly enhances mitochondrial bioenergetics, exerts potent antioxidative stress and anti-inflammatory effects, modulates neuroimmune-glial crosstalk, and strengthens cellular neuroprotective plasticity.
CONCLUSION: The synthesized evidence confirms the remarkable therapeutic potential of PBM in multiple sclerosis. The mechanistic insights derived from this review provide a rational basis for optimizing PBM therapeutic regimens and accelerating its clinical translation for the management of MS.